Ozempic

OZempic Semaglutide and Weight Loss
Semaglutide, the key component in Ozempic, has been demonstrated to decrease appetite and help users feel fuller sooner and for longer after meals, despite the product being marketed and approved for the treatment of diabetes. This implies that those on semaglutide are not only likely to eat less during meals, but also less inclined to snack in between meals, as they would feel fuller for longer. Patients may also consume fewer quantities than usual as a result of this decrease in appetite. When patients start taking Ozempic, they often have a much smaller total calorie deficit and start losing weight.

To what extent does Ozempic (semaglutide) aid in weight loss?

Several clinical trials have been conducted to demonstrate the efficacy of semaglutide as a medication for weight reduction. A study of this kind included 957 people who were over the age of 18, non-diabetic, and had a BMI of 30 or more. According to the study, 957 people with a BMI of 30 kg/m2 or higher participated in a clinical trial to see if semaglutide is an effective medication for weight loss. Adults without diabetes who were over the age of eighteen were eligible to participate. Across all dosages, 37–65% of semaglutide users saw an estimated 10% or more reduction in body weight. Comparatively, individuals who took a placebo—a drug that is not active—were the same weight. Just 10% of the people reported experiencing loss.

This trial found that semaglutide was well tolerated over 52 weeks when combined with dietary and physical activity counseling, and that it produced clinically meaningful weight loss when compared to placebo at all dosages.

Under the brand name Ozempic®, semaglutide is already approved to treat type 2 diabetes and may be prescribed in the UK. In the foreseeable future, a weight-loss pharmaceutical application has been filed to regulatory bodies and is undergoing approval.

Ozempic has enough clinical data to support its approval for weight reduction, and it is authorized in the US or UK. Those without type 2 diabetes have usually accepted it well, and the most recent clinical trials revealed no new safety issues. If an independent prescriber determines that it is clinically acceptable and reasonable, they may prescribe it for weight loss.